Physicians' Academy for Cardiovascular Education
Inflammation is receiving increasing attention for a potential role in residual CV risk. Follow recent insights into the importance of inflammation of CVD.
Anti-PCSK9 vaccination (AT04A) lowers LDL-c, atherosclerosis and inflammatory markers in mouse model for atherosclerosis. Phase I study into this vaccine has started
The phase III CANTOS study shows ACZ885 (canakinumab), in addition to standard care, reduces CV events in people with prior myocardial infarction and inflammatory atherosclerosis.
High frequency and long duration of tooth brushing were associated with a better endothelial function, implying that adequate tooth brushing may contribute to the prevention of CV events.
In addition to improving the lipoprotein and inflammatory profile, in vitro and in vivo experiments, as well as protein profiling of patient samples showed RVX-208 modulates the complement cascade.
VBWG ACC 2017 HIV-infected persons have increased CV risk. Even when HIV is adequately suppressed, chronic inflammation persists. Studying this condition can give insights in how to reduce CV risk and possibly HIV infection in these individuals.
RG7652, a PCSK9 antibody, dose-dependently reduced LDL-c, ApoB and Lp(a), but not inflammatory proteins, without concerning adverse events.
Biomarker levels, mainly those reflecting domains of cardiac stretch and inflammation, differ in HFpEF and HFrEF patients and possibly mirror different underlying pathophysiological processes.
Independent on fruit, vegetables, fish or dairy products, only consumption of alcohol and red wine were associated with lower endothelial dysfunction and low-grade inflammation in the Hoorn study.
Patients with familial dysbetalipoproteinaemia have increased arterial wall and cellular inflammation, as well as increased bone marrow activation.
Circulating monocytes of FH patients not on statins showed a pro-inflammatory phenotype and intracellular lipid accumulation, which was reversed upon treatment with PCSK9 antibodies.
In T2DM patients with albuminuria, liraglutide treatment associates with reductions in circulating levels of CV risk biomarkers.
First study in humans to show a link between activity in the amygdala to subsequent CV events, likely via upregulation of haemopoietic tissue activity and increased atherosclerotic inflammation.